Filing identity and reporting period
Important mismatch: The supplied filing is Graphite Bio, Inc.’s Form 10-Q for the quarter ended June 30, 2022, filed August 11, 2022. It is not identified as a filing by LENZ Therapeutics, Inc.; verify the issuer before relying on this summary.
Graphite Bio was a clinical-stage gene-editing company with no product-sales revenue. Its lead candidate, nula-cel, was in a Phase 1/2 trial for sickle cell disease (SCD); other programs were preclinical or earlier.
Financial performance and position
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Revenue | No product-sales revenue | No product-sales revenue | No product-sales revenue | No product-sales revenue |
| Research and development | $17.8M | $12.7M | $36.0M | $18.0M |
| General and administrative | $9.0M | $4.9M | $16.7M | $8.9M |
| Total operating expenses | $26.8M | $17.5M | $52.7M | $26.9M |
| Net loss | $25.9M | $17.5M | $51.8M | $37.2M |
| Net loss per share | $0.48 | $3.45 | $0.95 | $8.45 |
Margins are not meaningful given the absence of product-sales revenue. For the six months ended June 30, operating cash use was $43.3M, versus $21.8M a year earlier. Investing cash use was $258.9M, principally purchases of marketable securities; financing provided $0.4M, versus $385.3M in 2021, when the company completed its IPO and raised preferred-stock financing.
At June 30, 2022, cash and cash equivalents were $75.2M and marketable securities were $253.1M, totaling $328.3M. Current assets were $326.6M and current liabilities $12.1M. Total liabilities were $15.3M, including $8.2M of operating lease liabilities; the filing reports no borrowings. Accumulated deficit was $193.1M. Unrealized investment losses were $1.0M for the first half, recorded in other comprehensive loss.
Changes versus the comparable period
- Q2 net loss increased from $17.5M to $25.9M; first-half net loss increased from $37.2M to $51.8M.
- First-half R&D expense doubled to $36.0M, driven mainly by higher personnel costs and clinical-trial and contract-manufacturing activity. First-half G&A rose to $16.7M, primarily from personnel, consulting, professional-service and insurance costs.
- Operating cash use nearly doubled year over year. The large investing outflow primarily reflects conversion of cash into marketable securities, not solely operating consumption.
- Interest income contributed to 2022 other income; the 2021 comparison included a $10.3M non-cash loss from remeasurement of a preferred-stock tranche liability.
Outlook, commentary and risks
- Management anticipated initial nula-cel proof-of-concept data in mid-2023 and intended to file an IND for a second program by mid-2024.
- The filing gives differing runway statements: the liquidity note says available cash and securities were expected to fund the current plan for at least 12 months from issuance, while MD&A says funding was expected into Q4 2024. Both statements are based on the then-current operating plan.
- On July 21, 2022, the company filed a shelf registration for up to $300M and established an at-the-market program for up to $75M of common stock, with sales-agent commissions of up to 3%. No shares had been sold and no proceeds received through August 11, 2022.
- COVID-19 Omicron-related site staffing and enrollment challenges delayed the first nula-cel treatment and affected expected data timing. Key risks include clinical and regulatory failure or delay, gene-editing safety and off-target effects, reliance on third-party manufacturing and suppliers, financing and dilution, competition, and uncertain patent rights. The company reported no material legal proceedings and no material contingent legal liability known to management.
Investor verification priorities
- Confirm the issuer and filing match the intended LENZ Therapeutics 10-Q; this document names Graphite Bio, Inc. (Nasdaq: GRPH).
- Reconcile the stated cash runway—at least 12 months versus into Q4 2024—and review the assumptions behind each estimate.
- Check subsequent updates to nula-cel enrollment, trial timing, and the mid-2023 data target, including the effects of COVID-related delays.
- Monitor operating cash burn, clinical and manufacturing spending, investment values, and any use of the shelf or ATM that could dilute shareholders.
- Assess the status and terms of key Stanford and IDT licenses, options, milestones, manufacturing arrangements, and relevant intellectual-property challenges.